CohBar Inc
Change company Symbol lookup
Select an option...
CWBR CohBar Inc
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
BAC Bank of America Corp
WFC Wells Fargo & Co
ASB Associated Banc-Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.

Closing Price
$1.50
Day's Change
-0.03 (-1.96%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.60
Day's Low
1.46
Volume
(Light)
Volume:
316,976

10-day average volume:
714,024
316,976

Apple's stock gains after Wedbush's Ives boosts target to be the most bullish on the Street

6:55 am ET June 25, 2020 (MarketWatch)
Print

Shares of Apple Inc. (AAPL) edged up 0.4% in premarket trading Thursday, after Webush analyst Dan Ives raised his price target enough to make him the most bullish on Wall Street. Ives reiterated his outperform rating and lifted his target to $425 from $375, citing the 5G tailwinds, services momentum, a continues snapback in China and a potential "massive" pent-up iPhone 12 cycle heading into the fall. Ives's target is now the highest of the 40 analysts surveyed by FactSet; the next highest is China Renaissance Securities analyst Jason Sun at $410.60. "China remains a key ingredient in Apple's recipe for success as we estimate roughly 20% of iPhone upgrades will be coming from this region over the coming year," Ives wrote in a note to clients. He said the normalization in the supply chain, as the recovery from the worst of the COVID-19 effects continues, has been "impressive," and puts Apple "back in the driver's seat" to launch the 5G cycle in its typical mid-to-late September timeframe. And Ives said he believes the services business is worth $600 billion to $650 million, given the increasingly importance of this that revenue stream, which is getting "a new appreciation by investors" during this COVID-19 pandemic. The stock, which pulled back 1.8% on Wednesday from Tuesday's record close of $366.53, has run up 22.6% year to date while the Dow Jones Industrial Average has lost 10.8%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 25, 2020 06:55 ET (10:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.